Bazedoxifene / Conjugated Oestrogen
Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate
Conjugated oestrogens and bazedoxifene tablets are not recommended for prescribing for the treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin containing therapy is not appropriate. There is a lack of evidence demonstrating increased efficacy to mitigate the increased cost of the product.There are concerns about the adverse event profile of the product which introduces those of a new drug in addition to those already present due to the presence of oestrogen in the product.
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria